X4 Pharmaceuticals (XFOR) Competitors

$4.04 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.03 -0.01 (-0.25%)

As of 05/22/2026 07:06 PM Eastern

XFOR vs. VIR, ATAI, AMLX, MBX, and GHRS

Should you buy X4 Pharmaceuticals stock or one of its competitors? MarketBeat compares X4 Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with X4 Pharmaceuticals include Vir Biotechnology (VIR), Atai Beckley (ATAI), Amylyx Pharmaceuticals (AMLX), MBX Biosciences (MBX), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry.

How does X4 Pharmaceuticals compare to Vir Biotechnology?

X4 Pharmaceuticals (NASDAQ:XFOR) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

X4 Pharmaceuticals has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A
Vir Biotechnology	$68.56M	22.61	-$437.99M	-$3.13	N/A

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

X4 Pharmaceuticals currently has a consensus price target of $8.50, indicating a potential upside of 110.40%. Vir Biotechnology has a consensus price target of $20.25, indicating a potential upside of 120.35%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Vir Biotechnology has a net margin of -638.88% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Vir Biotechnology's return on equity of -53.31% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Vir Biotechnology had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for Vir Biotechnology and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.00 equaled Vir Biotechnology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

X4 Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

Summary

Vir Biotechnology beats X4 Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

X4 Pharmaceuticals has a net margin of -1,106.30% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 26.8% of Atai Beckley shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Atai Beckley had 8 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 9 mentions for Atai Beckley and 1 mentions for X4 Pharmaceuticals. Atai Beckley's average media sentiment score of 0.89 beat X4 Pharmaceuticals' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atai Beckley presently has a consensus target price of $16.00, indicating a potential upside of 270.37%. X4 Pharmaceuticals has a consensus target price of $8.50, indicating a potential upside of 110.40%. Given Atai Beckley's stronger consensus rating and higher possible upside, equities research analysts plainly believe Atai Beckley is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

X4 Pharmaceuticals has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$3.49M	455.99	-$660.05M	-$2.23	N/A
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A

Atai Beckley has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

Atai Beckley beats X4 Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Amylyx Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

X4 Pharmaceuticals presently has a consensus target price of $8.50, suggesting a potential upside of 110.40%. Amylyx Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 69.37%. Given X4 Pharmaceuticals' higher probable upside, equities research analysts plainly believe X4 Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

X4 Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market.

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Amylyx Pharmaceuticals' return on equity of -55.69% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 1 mentions for X4 Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.12 beat X4 Pharmaceuticals' score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

X4 Pharmaceuticals has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A

Summary

Amylyx Pharmaceuticals beats X4 Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to MBX Biosciences?

X4 Pharmaceuticals (NASDAQ:XFOR) and MBX Biosciences (NASDAQ:MBX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

X4 Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

X4 Pharmaceuticals has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

X4 Pharmaceuticals currently has a consensus price target of $8.50, suggesting a potential upside of 110.40%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 89.08%. Given X4 Pharmaceuticals' higher possible upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

MBX Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. MBX Biosciences' return on equity of -24.52% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
MBX Biosciences	N/A	-24.52%	-23.59%

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than MBX Biosciences. MarketBeat recorded 1 mentions for X4 Pharmaceuticals and 0 mentions for MBX Biosciences. X4 Pharmaceuticals' average media sentiment score of 0.00 equaled MBX Biosciences'average media sentiment score.

Company	Overall Sentiment
X4 Pharmaceuticals	Neutral
MBX Biosciences	Neutral

Summary

MBX Biosciences beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to GH Research?

GH Research (NASDAQ:GHRS) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

GH Research has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. GH Research's return on equity of -19.36% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

In the previous week, GH Research had 8 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 9 mentions for GH Research and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.00 beat GH Research's score of -0.86 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

56.9% of GH Research shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GH Research has higher earnings, but lower revenue than X4 Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A

GH Research presently has a consensus price target of $40.38, indicating a potential upside of 82.53%. X4 Pharmaceuticals has a consensus price target of $8.50, indicating a potential upside of 110.40%. Given X4 Pharmaceuticals' higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

GH Research beats X4 Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get X4 Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XFOR vs. The Competition

Export

Metric	X4 Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$381.05M	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.89	18.91	21.00	25.66
Price / Sales	10.85	329.32	615.84	98.33
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	2.26	7.09	10.37	7.14
Net Income	-$79.20M	$24.45M	$3.57B	$335.98M
7 Day Performance	9.78%	5.45%	6.00%	3.56%
1 Month Performance	-1.70%	2.43%	3.51%	2.54%
1 Year Performance	30.32%	62.98%	34.12%	35.05%

X4 Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XFOR X4 Pharmaceuticals	2.1991 of 5 stars	$4.04 flat	$8.50 +110.4%	+30.3%	$381.05M	$35.11M	N/A	80	Analyst Upgrade
VIR Vir Biotechnology	2.3231 of 5 stars	$8.77 -0.2%	$20.25 +130.9%	+104.2%	$1.48B	$68.56M	N/A	580
ATAI Atai Beckley	3.9905 of 5 stars	$4.15 +3.5%	$14.63 +252.4%	+109.7%	$1.48B	$3.49M	N/A	80	Positive News
AMLX Amylyx Pharmaceuticals	2.9971 of 5 stars	$12.86 -3.2%	$23.00 +78.8%	+155.7%	$1.48B	N/A	N/A	200	Positive News Gap Up
MBX MBX Biosciences	2.7596 of 5 stars	$30.98 -4.5%	$60.22 +94.4%	N/A	$1.47B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XFOR) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. VIR, ATAI, AMLX, MBX, and GHRS

How does X4 Pharmaceuticals compare to Vir Biotechnology?

Summary

How does X4 Pharmaceuticals compare to Atai Beckley?

Summary

How does X4 Pharmaceuticals compare to Amylyx Pharmaceuticals?

Summary

How does X4 Pharmaceuticals compare to MBX Biosciences?

Summary

How does X4 Pharmaceuticals compare to GH Research?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. VIR, ATAI, AMLX, MBX, and GHRS

How does X4 Pharmaceuticals compare to Vir Biotechnology?

Which has stronger earnings & valuation, XFOR or VIR?

Do institutionals and insiders have more ownership in XFOR or VIR?

Do analysts recommend XFOR or VIR?

Is XFOR or VIR more profitable?

Does the media favor XFOR or VIR?

Which has more risk & volatility, XFOR or VIR?

Summary

How does X4 Pharmaceuticals compare to Atai Beckley?

Is ATAI or XFOR more profitable?

Do institutionals & insiders believe in ATAI or XFOR?

Does the media refer more to ATAI or XFOR?

Do analysts recommend ATAI or XFOR?

Which has stronger valuation & earnings, ATAI or XFOR?

Which has more risk and volatility, ATAI or XFOR?

Summary

How does X4 Pharmaceuticals compare to Amylyx Pharmaceuticals?

Do analysts rate XFOR or AMLX?

Which has more risk & volatility, XFOR or AMLX?

Do insiders & institutionals hold more shares of XFOR or AMLX?

Is XFOR or AMLX more profitable?

Does the media favor XFOR or AMLX?

Which has stronger valuation & earnings, XFOR or AMLX?

Summary

How does X4 Pharmaceuticals compare to MBX Biosciences?

Do insiders & institutionals hold more shares of XFOR or MBX?

Which has more volatility & risk, XFOR or MBX?

Which has better valuation & earnings, XFOR or MBX?

Do analysts prefer XFOR or MBX?

Is XFOR or MBX more profitable?

Does the media favor XFOR or MBX?

Summary

How does X4 Pharmaceuticals compare to GH Research?

Is GHRS or XFOR more profitable?

Does the media refer more to GHRS or XFOR?

Which has more volatility & risk, GHRS or XFOR?

Do insiders and institutionals have more ownership in GHRS or XFOR?

Which has stronger valuation and earnings, GHRS or XFOR?

Do analysts recommend GHRS or XFOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools